Show simple item record

dc.contributor.authorKwok, Hang Fai (Henry)*
dc.date.accessioned2021-02-12T07:25:46Z
dc.date.available2021-02-12T07:25:46Z
dc.date.issued2019*
dc.date.submitted2019-12-09 11:49:15*
dc.identifier42564*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/61900
dc.description.abstractTargeted therapy has developed significantly in the last one and half decades, prescribing specific medications for treatment of particular diseases, such as cancer, diabetes, and heart disease. One of the most exciting recent developments in targeted therapies was the isolation of disease-specific molecules from natural resources, such as animal venoms and plant metabolites/toxins, for use as templates for new drug motif designs. In addition, the study of venom proteins/peptides and toxins naturally targeted mammalian receptors and demonstrated high specificity and selectivity towards defined ion channels of cell membranes. Research has also focsed intensely on receptors. The focus of this Special Issue of Toxins addressed the most recent advances using animal venoms, such as frog secretions, bee/ant venoms and plant/fungi toxins, as medicinal therapy. Recent advances in venom/toxin/immunotoxins for targeted cancer therapy and immunotherapy, along with using novel disease-specific venom-based protein/peptide/toxin and currently available FDA-approved drugs for combinationtreatments will be discussed. Finally, we included an overview of select promising toad/snake venom-based peptides/toxins potentially able to address the forthcoming challenges in this field. Both research and review articles proposing novelties or overviews, respectively, were published in this Special Issue after rigorous evaluation and revision by expert peer reviewers.*
dc.languageEnglish*
dc.subjectQH301-705.5*
dc.subjectQ1-390*
dc.subject.classificationthema EDItEUR::P Mathematics and Science::PS Biology, life sciencesen_US
dc.subject.othercane toad*
dc.subject.othern/a*
dc.subject.otherB cell non-Hodgkin lymphoma*
dc.subject.otherMalaysian cobras*
dc.subject.othercomplement system*
dc.subject.otherdecay accelerating factor*
dc.subject.otherneuroblastoma*
dc.subject.otheratopic dermatitis*
dc.subject.othercomplement dependent cytotoxicity*
dc.subject.otherantioxidant enzymes*
dc.subject.otherbacterial adhesion*
dc.subject.othercancer therapy*
dc.subject.otherN. kaouthia*
dc.subject.otheranuran skin secretion*
dc.subject.otherfrog*
dc.subject.otherApis mellifera syriaca*
dc.subject.othersolid phase extraction*
dc.subject.otherbee venom phospholipase A2 (bvPLA2)*
dc.subject.otherdisintegrin*
dc.subject.othertoad toxins*
dc.subject.otherimmunotoxins*
dc.subject.otherribosome-inactivating proteins*
dc.subject.otherantimicrobial peptide (AMP)*
dc.subject.otherdrug design*
dc.subject.otherMoxetumomab pasudotox*
dc.subject.othersnake venom*
dc.subject.otherantiviral activity*
dc.subject.otherin vitro effects*
dc.subject.otherbombesin-related peptide*
dc.subject.otheroxidative stress biomarkers*
dc.subject.otherhalf-life*
dc.subject.otherblood vessel formation*
dc.subject.othertarget therapy*
dc.subject.other2*
dc.subject.otherMYCN*
dc.subject.otherindolealkylamines*
dc.subject.otherHuachansu*
dc.subject.othermembrane attack complex*
dc.subject.otherbouganin*
dc.subject.otherbee venom*
dc.subject.otherSEM*
dc.subject.otheranticancer activity*
dc.subject.otherantimicrobial peptide*
dc.subject.otherhouse dust mite extract (DFE)*
dc.subject.othermannose receptor*
dc.subject.otherO. hannah*
dc.subject.otherbicarinalin*
dc.subject.othergastric cells*
dc.subject.othermelittin*
dc.subject.otherLC-ESI-MS*
dc.subject.otherdermaseptin*
dc.subject.othersmooth muscle*
dc.subject.otherapoptosis*
dc.subject.otheranticancer*
dc.subject.otherN. sumatrana*
dc.subject.otherHelicobacter pylori*
dc.subject.otherinflammation*
dc.subject.otherimmunotherapy*
dc.subject.otheratopic dermatitis (AD)*
dc.subject.otherimmunotoxin*
dc.subject.othermantle cell lymphoma*
dc.subject.otherclearance*
dc.subject.othermass spectrometry*
dc.subject.otherBougainvillea*
dc.subject.otherrRNA N-glycosylase activity*
dc.subject.otherfungal toxin*
dc.subject.otherskin inflammation*
dc.subject.othertargeted therapy*
dc.subject.other4-dinitrochlorobenzene (DNCB)*
dc.subject.otherBee venom*
dc.subject.otherVEGF*
dc.subject.otherChansu*
dc.subject.otherbufadienolides*
dc.subject.otherobsessive–compulsive disorder (OCD)*
dc.subject.otherBLF1*
dc.subject.otherantimicrobial activity*
dc.subject.otherorellanine*
dc.subject.otherVB6-845*
dc.subject.otheracute lymphoblastic leukemia*
dc.subject.otherribosome-inactivating protein*
dc.subject.otherCD206*
dc.subject.othermolecular cloning*
dc.subject.othercancer*
dc.subject.otherCD22*
dc.subject.othereIF4A*
dc.titleVenom and Toxin as Targeted Therapy*
dc.typebook
oapen.identifier.doi10.3390/books978-3-03921-190-6*
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0*
oapen.relation.isbn9783039211890*
oapen.relation.isbn9783039211906*
oapen.pages180*
oapen.edition1st*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/